Overview

Glimepiride 4 mg Tablets Under Fasting Conditions

Status:
Completed

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the relative bioavailability of glimepiride 4 mg tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA Pharmaceuticals USA) with that of AMARYL® tablets (Aventis) in healthy, adult, non-smoking subjects under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Glimepiride